New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:16 EDTCANFCan-Fite BioPharma submits Phase II study protocol with CF102
Can-Fite BioPharma announced that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted. The company plans to conduct the Phase II study in Israel, Europe and the US and will include 78 subjects with second-line treatment of advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. The study will investigate the efficacy and safety of CF102 vs. placebo. The US Food and Drug Administration has granted Orphan Drug designation for CF102, for the treatment of hepatocellular carcinoma. According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2B by 2015.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:13 EDTCANFCan-Fite BioPharma to present CF101 psoriasis data at EADV Congress
Can-Fite BioPharma announced that CEO Dr. Pnina Fishman will present data at the 24th European Academy of Dermatology and Venereology's Congress in Copenhagen, Denmark on Saturday, October 10. The presentation titled, "Treatment of Plaque-type Psoriasis with Oral CF101: Data from a Phase II/III Clinical Trial," will be part of the Late Breaking News session. Can-Fite previously reported positive data from further analysis of its completed Phase II/III study that suggests CF101 as a potential systemic therapy for patients with moderate-severe psoriasis, this despite the study not meeting its primary endpoint, as previously announced during the first quarter of 2015. Based on these findings, Can-Fite expects to complete the design of its Phase III study protocol by the end of 2015.
September 21, 2015
08:09 EDTCANFCan-Fite BioPharma announces $9M registered direct offering
Can-Fite BioPharma announced it will issue 2,068,966 registered American Depository Shares, or ADSs, of Can-Fite at a purchase price of $4.35 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one-half of an ADS. The warrants have an exercise price of $5.25 per ADS, shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. H.C. Wainwright & Co. acted as the exclusive placement agent in connection with this offering.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use